Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02864342 · ClinicalTrials.gov registry record · Phase 4
Adherence Study in COPD Patients
A Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 138
- Enrollment target
- 8
- Study locations
NCT02864342 is a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by AstraZeneca. The registered enrollment target is 138 participants, below the 647-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (79% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT02864342, a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 138 participants
- Enrollment target
- 8
- Study locations
Study Summary
A randomized clinical study to assess the impact of Symbicort® pMDI medication reminders on adherence in COPD patients
Conditions Studied
Interventions
- DEVICE Arm 1: BreatheMate device with application
- DEVICE Arm 2: BreatheMate device without application
Study Locations (8)
Florida
- Research Site - Clearwater
- Research Site - Tampa
Pennsylvania
- Research Site - Downingtown
- Research Site - Philadelphia
New Jersey
- Research Site - Marlton
New York
- Research Site - Brooklyn
North Carolina
- Research Site - Charlotte
South Carolina
- Research Site - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2016-08-12 |
| Est. Completion | 2017-10-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02864342
The ClinicalTrials.gov registry entry for NCT02864342 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (79% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Arm 1: BreatheMate device with application is the first listed.
NCT02864342 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02864342 about?
NCT02864342 is a clinical study titled "Adherence Study in COPD Patients". A randomized clinical study to assess the impact of Symbicort® pMDI medication reminders on adherence in COPD patients
What is the current status of trial NCT02864342?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 138 participants. The study started on 2016-08-12. Estimated completion is 2017-10-31.
What conditions does trial NCT02864342 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT02864342?
The interventions under investigation include: Arm 1: BreatheMate device with application (DEVICE), Arm 2: BreatheMate device without application (DEVICE).
Who is sponsoring clinical trial NCT02864342?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02864342 being conducted?
This trial has 8 study locations across Florida, New Jersey, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
COMPLETED · Phase 4
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.